{"filings":[{"id":973083,"accession_number":"0001193125-26-265861","cik":1861123,"company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","form_type":"8-K","filed_at":"2026-06-10T20:15:32+00:00","items":["5.02"],"status":"ready","headline":"Eikon Therapeutics appoints Ma. Fatima D. Francisco to Board as Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective June 15, 2026; serves until 2027 annual meeting.","Annual retainer of $50,000 paid quarterly; initial option for 85,937 shares at $8.96.","Option vests in 48 equal monthly installments subject to continued service.","Ms. Francisco will serve on the Compensation Committee of the Board.","No arrangements or related-person transactions with the Company disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":541386260.0000001,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":759477,"accession_number":"0001193125-26-249725","cik":1861123,"company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","form_type":"8-K","filed_at":"2026-06-01T11:30:25+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TeLuRide-005 Phase 2: ORR 63.1%, DCR 90.8% in 1L stage 4 NSCLC (n=65 evaluable).","Non-squamous cohort: ORR 55.6%, DCR 83.3%, median DOR >11 months at 13.6 months follow-up.","Squamous cohort: ORR 72.4%, DCR 100% with median follow-up 8.8 months (data maturing).","EIK1003 monotherapy (Cohort 1A): ORR 14.3% overall (26.7% PARP-naïve), median DOR 7.8 months in responders.","EIK1003 + paclitaxel (Cohort 1C): ORR 24.5% (29.6% in platinum-resistant ovarian, 19.2% in breast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541386260.0000001,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12884,"accession_number":"0001193125-26-216744","cik":1861123,"company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","form_type":"8-K","filed_at":"2026-05-11T20:05:32+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Eikon Therapeutics Q1 2026 net loss $83M, cash $596M; three oncology programs advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $83M (Q1 2026) vs $74.5M (Q1 2025); R&D expenses $70M (+24%) incl. $5M milestone to Impact Therapeutics.","Cash, equivalents and marketable securities $596M at March 31, 2026; expected to fund operations into H2 2027.","EIK1001: Phase 2 NSCLC trial fully enrolled; updated data at ASCO; Phase 2/3 trials in melanoma and NSCLC initiated.","EIK1003: Dose escalation completed; Phase 2 dose optimization trial first patient dosed; global site selection for Cohort 1D started.","EIK1005 (WRN helicase inhibitor): Phase 1/2 trial began dosing Feb 2026; two abstracts accepted for ASCO."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541386260.0000001,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110187,"accession_number":"0001193125-26-130449","cik":1861123,"company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eikon Therapeutics reports Q4/FY2025 net loss $79.7M/$333.6M; IPO raised $381M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders was $79.7M in Q4 2025 and $333.6M for full year 2025.","Cash, cash equivalents and marketable securities $336M as of Dec 31, 2025; added $381.2M from IPO in Feb 2026.","Completed enrollment of TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 NSCLC; data expected 2H 2026.","R&D expenses $65.2M in Q4 2025 (+21% YoY); $250.3M for FY2025 (+22% YoY).","Elected David W. Meline (former CFO of Moderna, Amgen, 3M) as independent director in December 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":541386260.0000001,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110186,"accession_number":"0001193125-26-041201","cik":1861123,"company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Eikon adopts amended charter and bylaws upon IPO closing on Feb 6, 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["IPO of common stock closed on February 6, 2026 per the company's S-1 registration.","Amended and restated certificate of incorporation filed with Delaware Secretary of State.","Amended and restated bylaws adopted effective as of February 6, 2026.","Both documents were previously approved by the board and stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":541386260.0000001,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}